We have studied the effects of concomitant blockade of 5-HT(3) and GABA(A) receptors on acetylcholine (ACh) release in the frontal cortex of rats with a selective cholinergic lesion. Lesions were performed by microinjection of the cholinergic toxin 192 IgG-saporin into the nucleus basalis magnocellularis. Single treatment with either the 5-HT(3) receptor antagonist ondansetron, 0.1 microg/kg, or the GABA(A) receptor benzodiazepine site antagonist flumazenil, 10 mg/kg, did not affect ACh release. However, the combined ondansetron + flumazenil administration significantly increased ACh release to a similar extent as a depolarising stimulus with K(+), 100 mM, at both 7 and 30 days post-lesion. Cortical perfusion with the combined ondansetron + flumazenil treatment also increased [(3)H]ACh efflux "in vitro" 30 days after lesion, suggesting that local events within the frontal cortex may participate in the interaction of ondansetron with GABAergic neurons, modulating ACh release in situations of cholinergic hypoactivity. No differences in the expression of 5-HT(3) and GABA(A) receptors in the frontal cortex were found after the cholinergic lesion. These results suggest that a combined ondansetron + flumazenil treatment would contribute to restoring a diminished cholinergic function and may provide a basis for using this treatment in the therapy of cognitive disorders associated with degeneration of the cholinergic system.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2004.03.014DOI Listing

Publication Analysis

Top Keywords

ondansetron flumazenil
16
ach release
16
frontal cortex
12
combined ondansetron
12
5-ht3 gabaa
8
gabaa receptors
8
cholinergic lesion
8
flumazenil treatment
8
cholinergic
7
ondansetron
6

Similar Publications

This meeting of the Federation of European Neuroscience Societies (FENS), hosted by the British Neuroscience Association (BNA), included a diverse range of neuroscience presentations including many of pharmacological relevance. The pharmacological characterization and mode of action of numerous drugs was presented, including IL-1ra, ARL-17477, zVAD-fmk, L-790984, CEP-1347, gacyclidine, NBI-30775, AWD-131-138, flumazenil, ondansetron, LY-367385, MPEP, and NBI-34060.

View Article and Find Full Text PDF

Single-dose parenteral pharmacological interventions for the prevention of postoperative shivering: a quantitative systematic review of randomized controlled trials.

Anesth Analg

September 2004

*Department of Anesthesiology, University of Würzburg, Würzburg, Germany; †Department of Anesthesia and Intensive Care, Philipps University of Marburg, Marburg, Germany; and.

Shivering is a frequent complication in the postoperative period. The relative efficacy of pharmacological interventions to prevent this phenomenon is not well understood. We performed a systematic search for full reports of randomized comparisons of prophylactic, parenteral, single-dose antishivering interventions with inactive control (placebo or no treatment).

View Article and Find Full Text PDF

We have studied the effects of concomitant blockade of 5-HT(3) and GABA(A) receptors on acetylcholine (ACh) release in the frontal cortex of rats with a selective cholinergic lesion. Lesions were performed by microinjection of the cholinergic toxin 192 IgG-saporin into the nucleus basalis magnocellularis. Single treatment with either the 5-HT(3) receptor antagonist ondansetron, 0.

View Article and Find Full Text PDF

Rationale: Cholinergic receptor blockade produces memory deficits in animal models. These deficits can be prevented by 5-HT3 receptor antagonists, such as ondansetron, which increases acetylcholine release. We investigated the effects on cognitive performance of combined treatments of ondansetron with either flumazenil, a GABA(A) receptor benzodiazepine site antagonist, or tacrine, a cholinesterase inhibitor, which are also able to prevent scopolamine-induced cognitive impairment.

View Article and Find Full Text PDF

ACh release from the rat frontal cortex was increased by both local, 0.1-1 microM, and systemic, 0.1-10 microg/kg, administration of the 5-HT(3) receptor antagonist ondansetron, reaching a maximum peak of 143% over basal values.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!